Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Mezzion Pharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	7,910	8,612	31,721	30,726	26,654
Other Revenue	-	-	-0	-	-
Revenue	7,910	8,612	31,721	30,726	26,654
Revenue Growth (YoY)	-8.15%	-72.85%	3.24%	15.28%	-6.92%
Cost of Revenue	6,529	6,701	27,836	31,040	22,956
Gross Profit	1,381	1,910	3,884	-313.44	3,698
Selling, General & Admin	15,973	14,958	16,142	19,510	17,283
Research & Development	1,260	294.04	938.97	2,217	1,956
Operating Expenses	18,221	16,210	18,373	23,018	20,496
Operating Income	-16,840	-14,300	-14,489	-23,331	-16,798
Interest Expense	-1,572	-300.79	-315.46	-423.44	-323.41
Interest & Investment Income	621.96	1,431	1,477	763.35	306.23
Currency Exchange Gain (Loss)	-71.67	286.56	996.94	3,177	3,700
Other Non Operating Income (Expenses)	-21,020	-1,180	-157.21	-1,410	90.67
EBT Excluding Unusual Items	-38,882	-14,062	-12,488	-21,225	-13,025
Gain (Loss) on Sale of Assets	44.05	-471.69	7.35	8.99	-1.08
Asset Writedown	-	-	-	-14,694	-
Pretax Income	-38,838	-14,534	-12,480	-35,910	-13,026
Income Tax Expense	-3,909	4,943	248.07	388.23	577.06
Earnings From Continuing Operations	-34,929	-19,477	-12,728	-36,298	-13,603
Net Income	-34,929	-19,477	-12,728	-36,298	-13,603
Net Income to Common	-34,929	-19,477	-12,728	-36,298	-13,603
Shares Outstanding (Basic)	30	30	28	27	27
Shares Outstanding (Diluted)	30	30	28	27	27
Shares Change (YoY)	0.95%	5.62%	5.63%	0.17%	2.63%
EPS (Basic)	-1160.00	-653.00	-450.74	-1357.81	-509.70
EPS (Diluted)	-1160.00	-653.00	-451.00	-1358.00	-510.00
Free Cash Flow	-16,725	-19,080	-11,553	-12,842	-15,429
Free Cash Flow Per Share	-555.46	-639.69	-409.10	-480.39	-578.14
Gross Margin	17.46%	22.18%	12.25%	-1.02%	13.88%
Operating Margin	-212.91%	-166.05%	-45.67%	-75.93%	-63.02%
Profit Margin	-441.61%	-226.17%	-40.13%	-118.13%	-51.03%
Free Cash Flow Margin	-211.46%	-221.56%	-36.42%	-41.80%	-57.89%
EBITDA	-15,852	-13,342	-12,942	-21,673	-15,212
EBITDA Margin	-200.42%	-154.93%	-40.80%	-70.54%	-57.07%
D&A For EBITDA	988.12	957.8	1,546	1,658	1,586
EBIT	-16,840	-14,300	-14,489	-23,331	-16,798
EBIT Margin	-212.91%	-166.05%	-45.67%	-75.93%	-63.02%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.